HEMOPHILIA AND OTHER BLOOD CLOTTING DISORDERS
Main Article Content
Abstract
Hemophilia and other blood clotting disorders are inherited and acquired conditions that significantly affect hemostasis. This paper reviews the molecular basis of these disorders, including F8, F9, and VWF gene mutations, their clinical manifestations, and the challenges of inhibitor formation. Advances in treatment strategies, such as factor replacement therapy, gene therapy, non-factor therapies (e.g., Emicizumab), and gene editing, are discussed. Emphasis is placed on personalized management, early diagnosis, and comprehensive care to improve patient outcomes and quality of life.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.Srivastava, A., et al. Guidelines for the management of hemophilia, Haemophilia, 2020.
2.Peyvandi, F., et al. Inherited bleeding disorders: Molecular basis and clinical management, Blood Reviews, 2019.
3.Bolton-Maggs, P.H.B., Hemophilia A and B: Diagnosis and management, British Journal of Haematology, 2018.
4.Lillicrap, D., Genetic and molecular aspects of hemophilia, Journal of Thrombosis and Haemostasis, 2017.
5.Blanchette, V.S., Clinical manifestations of hemophilia, Haemophilia, 2016.
6.Sadler, J.E., Von Willebrand disease: Pathophysiology and treatment, New England Journal of Medicine, 2005.
7.Rangarajan, S., et al. Gene therapy for hemophilia, New England Journal of Medicine, 2017.
8.Pasi, K.J., Emerging therapies in hemophilia, Blood, 2020.
9.Mahlangu, J.N., Emicizumab for hemophilia A, New England Journal of Medicine, 2018.
10.Shapiro, A.D., Non-factor therapies in hemophilia, Haemophilia, 2020.
11.Nurden, A., Platelet function disorders: Genomic insights, Blood Reviews, 2019.
12.Valentino, L.A., Future perspectives in bleeding disorder therapy, Haemophilia, 2022.